CTIA-4 blockade therapy; biology and clinical activity.
Cytotoxic T lymphocyte antigen-4 (CTLA-4) is a key inhibitory regulator for priming phase in T cell adaptive immunity against cancer. CTLA-4 blockade monotherapy or combination therapy with PD-1 blockade induces T cell activation and shows clinical activity in melanoma patients. Anti-CTLA-4 antibody is the first drug for immune checkpoint blockade and has been clinically used over the past decades. Several clinical characteristics and biomarkers in cancer immunotherapy were identified during developing CTLA-4 blockade therapy for mela- noma patients. Further roles of CTLA-4 blockade in other cancers are still to be determined. Well-designed clinical trial considering immune biology and findings from translational re- search is warranted to emerge potential efficacy of CTLA-4 blockade in cancer treatment.
PubMed Abstracts
PubMed Abstracts